{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.2","value":"60.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"title":"Future perspective, Factors I-II"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.9","value":"53.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"Future perspective, Factors III"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.5","value":"73.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"title":"Body image, Factors I-II"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.7","value":"73.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"Body image, Factors III"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.6","value":"31.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"title":"Symptoms of the disease, Factors I-II"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.1","value":"27.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"Symptoms of the disease, Factors III"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.9","value":"24.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"title":"Adverse effects of the treatment, Factors I-II"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.5","value":"29.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"Adverse effects of the treatment, Factors III"}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"}],"units":"Participants"}],"description":"The EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms, and side effects of treatment) with a recall period of previous week. Scores from each subscale were transformed from 0 to 100. For the functional scales, high scores represent improvement. For the symptom scales, higher scores represent worsening. Spanish Translated Version of EORTC Multiple Myeloma Module included 4 factors, each factor corresponds to questions related to the particular component of the scale. Factor I indicate symptoms. Factor II indicates future perspectives. Factor III indicate adverse effects of the treatment. Factor IV indicates adverse effects of the treatment and body image. Each of these factors were used for the clinical validity of the scale.","dispersionType":"Standard Deviation","groups":[{"description":"Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.","id":"OG000","title":"Multiple Myeloma (MM) Participants"}],"paramType":"MEAN","populationDescription":"All participants eligible for analyses were included. Number analyzed is the number of participants with data available for analyses for the specific category.","reportingStatus":"POSTED","timeFrame":"Day 1","title":"HRQOL Based on the Spanish Translated Version of EORTC Multiple Myeloma Module (EORTC QLQ-MY20)","type":"SECONDARY","unitOfMeasure":"score on a scale"}